Product class:
|
Medicinal product with marketing authorization
|
Medicinal product class:
|
Human medicine
|
Name of medicinal product:
|
ALFUZOSIN-TEVA
|
Active substances:
|
|
ATC code:
|
G04CA01
|
Dosage form:
|
prolonged-release tablet
|
Strength:
|
10mg
|
Legal status for supply*:
|
Subject to medicinal prescription
|
Summary of product characteristics (SPC):
|
(last updated April 18, 2023)
|
Package information leaflet (PIL):
|
EST (last updated April 18, 2023)
|
Labelling:
|
(last updated April 18, 2023)
|
Indication:
|
Treatment of the functional symptoms of benign prostatic hyperplasia (BPH).
|
Safety features:
|
Yes
|
Marketing authorization holder:
|
Teva Pharma B.V.
|
Marketing authorization number:
|
556507
|
Marketing authorization issued on:
|
August 24, 2007
|
Marketing authorization expires on:
|
Unlimited
|
Marketing authorization procedure type:
|
Mutual recognition
|
Assessment report:
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
1278165
|
ALFUZOSIN-TEVA
|
prolonged-release tablet
|
10mg 28TK
|
Prescription
|
|
|
|
|
|
1278176
|
ALFUZOSIN-TEVA
|
prolonged-release tablet
|
10mg 30TK
|
Prescription
|
100% 50%
|
11,20
|
22.03.2024
|
|
|
1278187
|
ALFUZOSIN-TEVA
|
prolonged-release tablet
|
10mg 50TK
|
Prescription
|
|
|
|
|
|
1278198
|
ALFUZOSIN-TEVA
|
prolonged-release tablet
|
10mg 100TK
|
Prescription
|
|
|
|
|
|
1337857
|
ALFUZOSIN-TEVA
|
prolonged-release tablet
|
10mg 90TK
|
Prescription
|
|
|
|
|
|
1379820
|
ALFUZOSIN-TEVA
|
prolonged-release tablet
|
10mg 10TK
|
Prescription
|
|
|
|
|
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere